Generate Biomedicines Inc., a biotechnology company backed by Flagship Pioneering, is seeking to raise as much as $425 million in an initial public offering, according to Bloomberg. The firm uses artificial intelligence in drug development and is capitalizing on surging listing activity in the sector.

The IPO comes as biotechnology firms increasingly turn to public markets to fund AI-driven drug discovery. Generate Biomedicines, founded in 2018, has positioned itself at the intersection of computational biology and pharmaceutical development. The company's AI platform aims to accelerate the design of novel therapeutics by predicting protein structures and functions.

This offering reflects broader momentum in AI-powered drug development, with investors showing renewed appetite for companies that can leverage machine learning to streamline pharmaceutical research. The $425 million target suggests Generate Biomedicines is seeking substantial capital to scale its operations and advance its pipeline of AI-designed therapeutics.